BioSpace News Archive

The top COVID-19 story is on the pause of the Johnson & Johnson vaccine in the U.S. over rare blood clots. But it’s not the only news. Here’s a look.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

This is by far the most exciting time in our history as Jubilant Biosys, and certainly the most exciting message Biosys has ever announced simply because of the sheer scale of transformation that we’ve taken on. It’s massive, very achievable, and ultimately truly transformative for us as colleagues, professionals, as an organization, and to our customers.

Following the success of its authorized vaccine against COVID-19, Moderna is boosting its efforts to develop preventative drugs in other viral areas.

Common stock in the new combined company, Tango Therapeutics, Inc., will soon be listed on Nasdaq under ticker “TNGX.”

Under the terms of the deal, SciNeuro is paying Lilly cash upfront as well as various milestone payments and royalties. No financial details were disclosed.

The approval marks the second approval for Trodelvy, which Gilead gained through its $21 billion acquisition of Immunomedics.

The main concern remains the KN95 mask’s regulation and lack of standardization. Also, to know if you can reuse KN95 mask or not, follow this article.

Mayo Clinic announced Wednesday that it has launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.

The new financing brings the company’s total funding to approximately $350 million, placing Benchling even closer to an initial public offering.